中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 7
Jul.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(7): 1523-1528

Effect of systemic therapeutic drugs for hepatocellular carcinoma on portal hypertension

DOI: 10.3969/j.issn.1001-5256.2023.07.002

  • National Cancer Center/National Clinical Research Center for Cancer/Department of Interventional Therapy, Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Research funding:

National key R&D Program of China (2020YFC0122303)

More Information
  • Corresponding author: YANG Zhengqiang, ntdoctoryang@hotmail.com(ORCID: 0000-0001-9103-3534); LI Xiao, simonlixiao@gmail.com(ORCID: 0000-0001-9420-9558)
  • Received Date: 2023-05-10
  • Accepted Date: 2023-06-11
  • Published Date: 2023-07-20
    Abstract
  • The vast majority of patients with hepatocellular carcinoma (HCC) in China originate from hepatitis B cirrhosis, while 90% of cirrhotic patients may develop portal hypertension, and the HCC patients with portal hypertension account for 15%-30%. Portal hypertension is a group of clinical syndromes characterized by elevated portal venous pressure and formation of portal-systemic collateral circulation, and it is one of the most important complications of liver cirrhosis. HCC and portal hypertension affect each other, and portal hypertension seriously affects the prognosis of HCC patients. The development of systemic treatment regimens for HCC provides more treatment options for patients with advanced HCC, including molecular-targeted drug therapy, immunotherapy, and chemotherapy. Different systemic therapeutic drugs for HCC have different impacts on portal hypertension, and this article reviews the effect of commonly used systemic therapeutic drugs for HCC on portal hypertension.

     

    • FullText(HTML)
  • loading
    • References(40)
  • [1]
    VOGEL A, MEYER T, SAPISOCHIN G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400(10360): 1345-1362. DOI: 10.1016/S0140-6736(22)01200-4.
    [2]
    China Anti Cancer Association Liver Cancer Professional Committee of International Hepatobiliary Pancreatic Association China Branch, China Research Hospital Hepatobiliary Surgery Professional Committee, China Research Hospital Virus and Tumor Professional Committee. Chinese Expert Consensus on antiviral therapy for hepatitis B virus related hepatocellular carcinoma (2023 version)[J]. Chin Hepatol, 2023, 28(1): 1-10. DOI: 10.3969/j.issn.1008-1704.2023.01.001.

    国际肝胆胰协会中国分会中国抗癌协会肝癌专业委员会, 中国研究型医院肝胆外科专业委员会, 中国研究型医院病毒与肿瘤专业委员会. 乙型肝炎病毒相关肝细胞癌抗病毒治疗中国专家共识(2023年版)[J]. 肝脏, 2023, 28(1): 1-10. DOI: 10.3969/j.issn.1008-1704.2023.01.001.
    [3]
    LI T, CHEN H. Liver transplantation for the treatment of portal hypertension in liver cirrhosis[J]. J Surg Concepts Pract, 2021, 26(3): 189-194. DOI: 10.16139/j.1007-9610.2021.03.002.

    李涛, 陈皓. 肝硬化门静脉高压症的肝移植治疗[J]. 外科理论与实践, 2021, 26(3): 189-194. DOI: 10.16139/j.1007-9610.2021.03.002.
    [4]
    WANG WD. Diagnosis and treatment of hepatocellular carcinoma with portal hypertension[J]. World Chin J Dig, 2018, 26(24): 1429-1433. DOI: 10.11569/wcjd.v26.i24.1429.

    王卫东. 肝癌合并门静脉高压症的诊治现状[J]. 世界华人消化杂志, 2018, 26(24): 1429-1433. DOI: 10.11569/wcjd.v26.i24.1429.
    [5]
    SANGRO B, SAROBE P, HERVÁS-STUBBS S, et al. Advances in immunotherapy for hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(8): 525-543. DOI: 10.1038/s41575-021-00438-0.
    [6]
    BRUIX J, QIN S, MERLE P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064): 56-66. DOI: 10.1016/S0140-6736(16)32453-9.
    [7]
    LLOVET J M, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390.
    [8]
    KUDO M, FINN RS, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173. DOI: 10.1016/S0140-6736(18)30207-1.
    [9]
    ABOU-ALFA GK, MEYER T, CHENG AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. N Engl J Med, 2018, 379(1): 54-63. DOI: 10.1056/NEJMoa1717002.
    [10]
    GANA JC, SERRANO CA, LING SC. Angiogenesis and portal- systemic collaterals in portal hypertension[J]. Ann Hepatol, 2016, 15(3): 303-313. DOI: 10.5604/16652681.1198799.
    [11]
    ZHU Y, CHENG Y, LI AM, et al. Therapeutic effect of sorafenib on portal hypertension: research progress and mechanisms[J]. J South Med Univ, 2014, 34(1): 133-136. DOI: 10.12122/j.issn.1673-4254.2014.01.030.

    朱云, 程旸, 李爱民, 等. 索拉非尼对门静脉高压症的治疗作用及其机制[J]. 南方医科大学学报, 2014, 34(1): 133- 136. DOI: 10.12122/j.issn.1673-4254.2014.01.030.
    [12]
    THABUT D, ROUTRAY C, LOMBERK G, et al. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis[J]. Hepatology, 2011, 54(2): 573-585. DOI: 10.1002/hep.24427.
    [13]
    REIBERGER T, ANGERMAYR B, SCHWABL P, et al. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats[J]. J Hepatol, 2009, 51(5): 865-873. DOI: 10.1016/j.jhep.2009.06.024.
    [14]
    MEJIAS M, GARCIA-PRAS E, TIANI C, et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats[J]. Hepatology, 2009, 49(4): 1245-1256. DOI: 10.1002/hep.22758.
    [15]
    HENNENBERG M, TREBICKA J, STARK C, et al. Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis[J]. Br J Pharmacol, 2009, 157(2): 258-270. DOI: 10.1111/j.1476-5381.2009.00158.x.
    [16]
    CORIAT R, GOUYA H, MIR O, et al. Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib[J]. PLoS One, 2011, 6(2): e16978. DOI: 10.1371/journal.pone.0016978.
    [17]
    HIDAKA H, NAKAZAWA T, KANEKO T, et al. Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study[J]. J Gastroenterol, 2012, 47(9): 1030-1035. DOI: 10.1007/s00535-012-0563-6.
    [18]
    PINTER M, SIEGHART W, REIBERGER T, et al. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma-a pilot study[J]. Aliment Pharmacol Ther, 2012, 35(1): 83-91. DOI: 10.1111/j.1365-2036.2011.04896.x.
    [19]
    D'AMICO M, MEJIAS M, GARCIA-PRAS E, et al. Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats[J]. Am J Physiol Gastrointest Liver Physiol, 2012, 302(10): G1191-G1198. DOI: 10.1152/ajpgi.00252.2011.
    [20]
    KUDO M. Lenvatinib may drastically change the treatment landscape of hepatocellular carcinoma[J]. Liver Cancer, 2018, 7(1): 1-19. DOI: 10.1159/000487148.
    [21]
    OHYA K, KAWAOKA T, NAMBA M, et al. Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy[J]. Sci Rep, 2019, 9(1): 12101. DOI: 10.1038/s41598-019-48045-z.
    [22]
    ALLAIRE M, RUDLER M, THABUT D. Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses[J]. Liver Int, 2021, 41(8): 1734-1743. DOI: 10.1111/liv.14977.
    [23]
    HIDAKA H, UOJIMA H, NAKAZAWA T, et al. Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: A prospective cohort study[J]. Hepatol Res, 2020, 50(9): 1083-1090. DOI: 10.1111/hepr.13531.
    [24]
    USCHNER FE, SCHUELLER F, NIKOLOVA I, et al. The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension[J]. Oncotarget, 2018, 9(90): 36220-36237. DOI: 10.18632/oncotarget.26333.
    [25]
    APTE RS, CHEN DS, FERRARA N. VEGF in signaling and disease: beyond discovery and development[J]. Cell, 2019, 176(6): 1248-1264. DOI: 10.1016/j.cell.2019.01.021.
    [26]
    ROSMORDUC O. Antiangiogenic therapies in portal hypertension: a breakthrough in hepatology[J]. Gastroenterol Clin Biol, 2010, 34(8-9): 446-449. DOI: 10.1016/j.gcb.2010.05.007.
    [27]
    LARREY E, CAMPION B, EVAIN M, et al. A history of variceal bleeding is associated with further bleeding under atezolizumab-bevacizumab in patients with HCC[J]. Liver Int, 2022, 42(12): 2843-2854. DOI: 10.1111/liv.15458.
    [28]
    CAMPION B, LARREY E, WAGNER M, et al. Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: A "menage à trois"![J]. Clin Res Hepatol Gastroenterol, 2022, 46(2): 101785. DOI: 10.1016/j.clinre.2021.101785.
    [29]
    FURUSAWA A, NAGANUMA A, SUZUKI Y, et al. Two cases of rapid progression of esophageal varices after atezolizumab-bevacizumab treatment for hepatocellular carcinoma[J]. Clin J Gastroenterol, 2022, 15(2): 451-459. DOI: 10.1007/s12328-022-01605-9.
    [30]
    SUZUKI H, IWAMOTO H, SHIMOSE S, et al. Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review[J]. Front Oncol, 2022, 12: 948293. DOI: 10.3389/fonc.2022.948293.
    [31]
    QIN S, BAI Y, LIM HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31(28): 3501-3508. DOI: 10.1200/JCO.2012.44.5643.
    [32]
    QIN S, CHENG Y, LIANG J, et al. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study[J]. Oncologist, 2014, 19(11): 1169-1178. DOI: 10.1634/theoncologist.2014-0190.
    [33]
    Chinese Society of Clinical Oncology. Dignosis and treatment guidelines for primary liver cancer 2022[M]. People's Health Publishing House, 2022: 90-91.

    中国临床肿瘤协会(CSCO). 原发性肝癌诊疗指南2022[M]. 人民卫生出版社, 2022: 90-91.
    [34]
    LYU N, WANG X, LI JB, et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase iii trial (FOHAIC-1)[J]. J Clin Oncol, 2022, 40(5): 468-480. DOI: 10.1200/JCO.21.01963.
    [35]
    SLADE JH, ALATTAR ML, FOGELMAN DR, et al. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury[J]. Clin Colorectal Cancer, 2009, 8(4): 225-230. DOI: 10.3816/CCC.2009.n.038.
    [36]
    MADBOULY KM, HUSSEIN AM, ZEID A. Colorectal cancer surgery in portal hypertensive patients: does adjuvant oxaliplatin affect prognosis?[J]. Dis Colon Rectum, 2013, 56(5): 577-585. DOI: 10.1097/DCR.0b013e318286f8fc.
    [37]
    YAZAKI T, KAWASHIMA K, ISHIMURA N, et al. Oxaliplatin-related portal hypertension complicated with esophageal varices and refractory massive ascites[J]. Intern Med, 2022, 61(21): 3225-3231. DOI: 10.2169/internalmedicine.9266-21.
    [38]
    FUENTES-LACOUTURE MC, BARRERA-GARAVITO EC, GOMEZ A, et al. Non-cirrhotic portal hypertension in a patient with colonic carcinoma treated with oxaliplatin[J]. J Med Cases, 2021, 12(3): 99-101. DOI: 10.14740/jmc3630.
    [39]
    MORIOKA D, IZUMISAWA Y, YAMAGUCHI K, et al. Surgical intervention for portal hypertension caused by oxaliplatin-based chemotherapy: a case report and a review of literature regarding radiological and/or surgical interventions for oxaliplatin-associated portal hypertension[J]. Clin J Gastroenterol, 2020, 13(5): 799-805. DOI: 10.1007/s12328-020-01157-w.
    [40]
    HUANG X, LI F, WANG L, et al. Endoscopic treatment of gastroesophageal variceal bleeding after oxaliplatin-based chemotherapy in patients with colorectal cancer[J]. Endoscopy, 2020, 52(9): 727-735. DOI: 10.1055/a-1157-8611.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (589) PDF downloads(139) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return